文献速递青光眼

一种紧凑型全眼球灌注系统用于评估房水流出易度的药理学反应

A Compact Whole-Eye Perfusion System to Evaluate Pharmacologic Responses of Outflow Facility.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2017-01-01

本研究开发了一种紧凑、可扩展的眼球灌注系统,可在1平方米 footprint 内同时测量20只眼,并在6 mmHg固定眼压下用牛眼和猪眼验证了系统。Y-39983使犊牛眼流出量最高增加31%,ET-1使流出量最高降低79%且可被安立生坦阻断,NO供体SNAP和SIN-1预处理可抑制ET-1效应70%至80%。

要点

  • 紧凑型灌注系统可同时测量20只眼,占地1平方米
  • Y-39983使犊牛眼流出量最高增加31%
  • ET-1使流出量最高降低79%,安立生坦可阻断该效应

核心结论

  • 紧凑型眼球灌注平台可高效识别影响流出易度的化合物,并可能促进发现新的青光眼疗法。

研究设计与样本

  • 在固定眼压6 mmHg下,通过流量传感器测量流量,使用牛眼和猪眼验证系统对多种药物的流出反应。

主要发现

  • 仪器设计允许同时测量20只眼,占地1平方米。
  • 与溶剂对照相比,Y-39983使犊牛眼流出量最高增加31%。
  • ET-1使流出量最高降低79%,安立生坦预处理可阻断该反应,提示ETA受体的作用。
  • NO供体SNAP和SIN-1预处理可抑制ET-1效应70%至80%。
  • 在成年牛眼和猪眼中也观察到ET-1和安立生坦的类似效应。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To discover novel therapies that lower IOP by increasing aqueous humor outflow facility, ex vivo ocular perfusion systems provide a valuable tool. However, currently available designs are limited by their throughput. Here we report the development of a compact, scalable perfusion system with improved throughput and its validation using bovine and porcine eyes. METHODS: At a fixed IOP of 6 mm Hg, flow rate was measured by flow sensors. We validated the system by measuring the outflow responses to Y-39983 (a Rho kinase inhibitor), endothelin-1 (ET-1), ambrisentan (an antagonist for endothelin receptor A [ETA]), sphigosine-1-phosphate (S1P), JTE-013 (antagonist for S1P receptor 2 [S1P2]), S-nitroso-N-acetylpenicillamine (SNAP, a nitric oxide [NO] donor), and 3-Morpholino-sydnonimine (SIN-1, another NO donor). RESULTS: The instrument design enabled simultaneous measurements of 20 eyes with a footprint of 1 m2. Relative to vehicle control, Y-39983 increased outflow by up to 31% in calf eyes. On the contrary, ET-1 decreased outflow by up to 79%, a response that could be blocked by pretreatment with ambrisentan, indicating a role for ETA receptors. Interestingly, the effect of ET-1 was also inhibited by up to 70% to 80% by pretreatment with NO donors, SNAP and SIN-1. In addition to testing in calf eyes, similar effects of ET-1 and ambrisentan were observed in adult bovine and porcine eyes. CONCLUSIONS: The compact eye perfusion platform provides an opportunity to efficiently identify compounds that influence outflow facility and may lead to the discovery of new glaucoma therapies.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhou EH, Paolucci M, Dryja TP, et al. A Compact Whole-Eye Perfusion System to Evaluate Pharmacologic Responses of Outflow Facility. Invest Ophthalmol Vis Sci. 2017. PMID: 28605810. doi:10.1167/iovs.16-20974

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。